What question did this study set out to answer?

This study aimed to determine the latency between NGS MRD positivity and relapse in acute lymphoblastic leukemia patients.

December 8, 2025BloodOpen Access

Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring

View Full Paper

Ask AI

Bookmark

This study aimed to determine the latency between NGS MRD positivity and relapse in acute lymphoblastic leukemia patients.
Retrospective analysis of patients with acute lymphoblastic leukemia (ALL) in CR1.
Evaluated NGS MRD using clonoSEQ on banked samples from MRD-negative patients.
Time to relapse was modeled using Kaplan-Meier analysis.
Median time from NGS MRD positivity to relapse was 3.6 months.
71% of patients were NGS MRD-positive before relapse.
Monitoring frequency of every 3 months may help detect MRD recurrence.

No takes yet. Share an insight, caveat, or question.

Retrospective analysis shows NGS MRD predicts relapse in acute lymphoblastic leukemia, suggesting monitoring every 3 months is necessary.

Jamison et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark